Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MELITAC 12.1 peptide vaccine
- Development stage
- Unknown
- Lead developer
- University of Virginia
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
**MELITAC 12.1 peptide vaccine** is an investigational therapeutic multipeptide melanoma vaccine developed at the University of Virginia. It contains 12 class I MHC-restricted melanoma-associated peptide epitopes derived from melanocytic differentiation antigens and cancer-testis antigens, plus a class II MHC-restricted tetanus toxoid helper peptide. The vaccine is intended to prime and expand tumor-antigen-specific cytotoxic T-cell responses against melanoma cells presenting these antigens. It was studied with immune adjuvants including lipopolysaccharide, poly-ICLC, and incomplete Freund's adjuvant in melanoma trials. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/melitac-121-peptide-vaccine))
- Other names
- MELITAC 12.1 peptide vaccineMELITAC12.1 peptide vaccineMELITAC-12.1 peptide vaccine
02
Targets
MAGEA1 (Melanoma-associated antigen 1)Melanocyte protein PMEL (gp100) epitopeHLA-A*03:01 (DARKFOX-A3 peptide-HLA-A*03:01 complex)
Beyond the preview
Go deeper on MELITAC 12.1 peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MELITAC 12.1 peptide vaccine.